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Mathematical models provide a means to
understand the human immunodeficiency virus
(HIV)-infected immune system as a dynamic pro-
cess. Models formulated as differential equations
for the dynamic interactions of CD4+ lymphocytes
and virus populations are useful in identifying
essential characteristics of HIV pathogenesis
and chemotherapy. Recent clinical studies have
produced new insight into the dynamics of these
virus populations during HIV infection (1-3).
Turnover rates and lifespans of infected CD4+ T
cells and virus have been identified by measuring
their rates of change in patients undergoing
strong antiviral mono-therapy. The determination
of these rates showed that large numbers of
CD4+ T cells and virus are gained and lost each
day throughout the course of HIV infection (4,5);
these findings have profoundly influenced stra-
tegies for therapy (6). It is now recognized that
chemotherapeutic agents must strongly suppress
viral production before rapidly appearing viral
mutants evolve to drug resistance. Recent clini-
cal trials have accomplished this goal by using
combined drug therapy. Ongoing trials with com-
binations of drugs have shown sharp declines, in
some patients, of viral counts to nondetectable
levels within several weeks of treatment; these
levels were sustained for 1 year or more (5,7,8).
At the same time, CD4+ T-cell counts have risen
markedly before gradually leveling off (5,7,8).
This apparent remission of HIV infection offers
hope for the chronic control or even eradication
of HIV (6). The issue of stopping treatment
after such extended periods of remission, how-
ever, is yet to be resolved (8).
The Model
Our model of treatment distinguishes quali-
tatively two treatment outcomes indicated by
clinical trials. The first is resistance. Examples of
resistance for three-drug combined therapy are
reported for completed clinical trials by Collier et
al. (9). In these trials, there was on average an
increase of CD4+ T-cell counts by approximately
30% (peaking at approximately 8 weeks and
returning to baseline at approximately 40 weeks)
and a decrease of plasma virus by approximately
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70% (peaking at approximately 4 weeks and
recovering to half baseline at approximately 40
weeks). The second treatment outcome is remis-
sion. Examples of remission are indicated in
preliminary reports of ongoing clinical trials
(5,7,8,10). In these trials, 1) plasma virus
decreased sharply to nondetectable levels in 2 to
4 weeks, and these levels were sustained for
periods of 1 year or more, and 2) CD4+ T-cell
counts increased steadily by 100/mm3 or more
before gradually leveling off to below normal
levels (this below normal recovery is believed to
be due to an impaired production of new CD4+ T
cells from the thymus and other sources [11,12];
this assumption is incorporated into the model).
The model consists of differential equations
for the variables T(t) (the CD4+ T-cell population
uninfected by virus at time t), Ts(t) (the CD4+ T-
cell population infected by drug-sensitive virus at
time t), Tr(t) (the CD4+ T-cell population infected
by drug-resistant virus at time t), Vs(t) (the drug-
sensitive virus population at time t), and Vr(t)
(the drug-resistant virus population at time t).
All these virus populations reside in the cir-
culating blood, in which the values of uninfected
CD4+ T cells and virus can be clinically measured.
The assumptions of the model and its equations
are given in the Appendix.
The model incorporates recent clinically
determined dynamic information about the HIV-
infected immune system. The essential elements
are as follows. After an initial period of acute
viremia in the first few weeks after seroconversion,
CD4+ T-cell counts decline gradually from
approximately 600 to 800/mm3 to 0/mm3 over
approximately 10 years (11) (normal CD4+ T-cell
counts are 800 to 1,200/mm3). The decline of
CD4+ T cells is more rapid early in the infection
(13). Infected CD4+ T cells constitute 4% or less of
the CD4+ T-cell population (14). The half-life of
an infected CD4+ T cell is approximately 2 days
(1-3,6). After the initial viremia, plasma virus
increases from below 50/mm3 to 1,000/mm3 or
more during the variable course of infection with
a sharp increase toward the end of the
symptomatic phase (11). The lifespan of a virus
outside the cell is about 7.2 hrs (1-3).
A typical untreated disease course based
upon CD4+ T-cell counts and viral level is
simulated in Figure 1a,b (the initial period of
viremia is not included in the model). The
simulation in Figure 1a,b is in close agreement
with a typical disease course (11). The initial
virus level is determined by the model’s
parameters, which do not change throughout the
course of the disease. This assumption is consis-
tent with recent clinical findings that disease
prognosis is correlated to a set-point of virus level
established in each patient soon after the initial
viremia, and viral levels and replication rates
remain relatively stable after the set-point
(5,8,15,16). In the model, different set-points are
obtained by varying key parameter values.
In the model, treatment is incorporated as
the reduction of two separate rates. The
reduction of these rates provides treatment
control variables corresponding to the intensity
and velocity of drug action. The variables are the
rate at which virus infects uninfected CD4+ T
cells and the rate of virus influx into the plasma
from the external lymphoreticular system.
Reduction of this second rate is the most
important for treatment outcome, since it is
believed that as much as 98% of the virus in the
circulating blood is contributed by the external
lymphoid compartment (5,8,17). In the simu-
lations, the dynamics in the lymphoid compart-
ment are modeled as a viral source term rather
than mechanistically, since limited data are
available for this compartment (18). Models of
combined plasma-lymph compartment dynamics
will appear in future work. When treatment
begins, the model assumes that a proportion of
drug-sensitive virus mutates to drug-resistant
virus. This proportion is also a treatment control
variable corresponding to the combination of
drugs used or the presence of genetic diversity at
different disease stages (19).
The model distinguishes primarily between
resistance and remission in the assumption of a
threshold condition for the virus population in
the plasma (and thus for the virus population in
the lymphoid compartment). The threshold con-
dition is incorporated into the rate that controls
the contribution of drug-resistant virus from the
external lymphoid compartment to the plasma.
When treatment drives the plasma virus level
below the threshold, the drug-resistant virus
population does not emerge, and the drug-
sensitive virus population falls to near 0. This
threshold cannot be reached simply by gradually
lowering the drug-sensitive virus population.
Two additional factors must be considered: 1)
when the virus population is above threshold, the
high mutational capacity and short lifespan of
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resistant variants; and 2) as the virus population
approaches the threshold, Darwinian competition
gives competitive advantage to the resistant viral
strain as the sensitive viral strain diminishes in
fitness and in numbers.
To reach the threshold, the virus population
must be brought down extremely fast before
mutation and selection pressure allow resistant
virus to propagate in the drug-altered environ-
ment. In the simulations, this rapid fall to the
threshold can be achieved if treatment inhibits the
rate of viral influx from the external lymphoid
compartment sufficiently fast. The threshold
value depends on the drugs used and the capacity
of the virus to mutate against these drugs. In
some patients, plasma levels were reduced by
99.9% or more, yet remission did not occur (1,2).
In these cases, there may have been an extremely
low threshold specific to the drugs used or a
disproportionately lower suppression of virus in
the lymphoid compartment than in the plasma.
The Simulations
Computer simulations of treatment are given
in Figure 1c,d and Figures 2-5. The initial values
at the start of treatment for the simulations are
obtained from the simulation in Figure 1a,b. In
all the simulations, the parameters are the same,
except for the parameters controlling treatment
and the resistance mutation.
Figure 1a,b. A simulation of HIV dynamics for the model (A.1) - (A.3) with T(0) = 600/mm3 and Vs(0) = 10/mm3. The
curves correspond to data in (11). The set-point of the virus is in the middle range (15) and corresponds to a typical
disease progression of about 9 years. The contribution to the plasma virus from the external lymphoid
compartment is more than 90%, as may be computed from equation (A.3). The curves T(t) and Vs(t) are
approximately inversely proportional, as may be seen from equation (A.3) (the inverse proportionality is specific
to a given set-point). In c,d, a simulation of a combined drug treatment corresponds to data in (9). The treatment
begins with the uninfected CD4+ T-cell count at 200/mm3, the infected CD4+ T-cell count at 9.5/mm3, and the virus
level at 34/mm3 (these values are obtained from the simulation in a, b at 7.9 years). In d, the heavy line is the total
virus population, the thin line is the wild-type virus population, and the dashed line is the drug-resistant virus
population. Complete replacement of wild-type virus by resistant virus occurs by week 5. The treatment
parameters are c1=.5, c2=.025, c3=.15, and the resistance mutation parameter is q=10-7.276 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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In Figure 1c,d, resistance is simulated. The
simulation corresponds to composite data given
(9) for patients receiving the drug combination
saquinavir, zidovudine, and zalcitabine (the first
is a protease inhibitor and the other two are
reverse transcriptase inhibitors). Despite an
impressive increase in the CD4+ T-cell counts in
Figure 1c (significantly higher than typically
seen with zidovudine alone [20-23]), the reduc-
tion of viral influx from the external lymphoid
compartment is not fast enough or strong enough
to bring the virus below the threshold for remis-
sion. The viral level thus rebounds after a few
weeks, and the T-cell population resumes a decline.
In Figure 2, resistance is simulated cor-
responding to data for patients receiving therapy
with strong reverse transcriptase inhibitors (10).
In these simulations, the reduction of the viral
influx from the external lymphoid compartment
is higher than in the simulation in Figure 1d,
which means that the effect of the drug is
stronger and the decrease of the virus level is
faster. The resistance mutation parameter is also
assumed to be higher than in Figure 1c,d, which
means that resistance develops sooner. The
exponential rates of increase of CD4+ T-cell
counts in Figure 2a are inversely correlated to
CD4+ T-cell starting values, as are the times to
the appearance of resistance. The exponential
rates of viral decay (Figure 2b), as indicated by
the slopes of their logarithmic plots, are approxi-
mately parallel and thus not correlated to
Figure 2. Four simulations corresponding to therapy (2). The simulations have a common viral set-point of disease
progression with the treatment starting values T(0) = 306/mm3 and Vs(0) = 21/mm3 (obtained from Figure 1a,b at 5.8
years), T(0) = 217/mm3 and Vs(0) = 31/mm3 (obtained from Figure 1a,b at 7.7 years), T(0) = 100/mm3 and Vs(0) = 69/mm3
(obtained from Figure 1a,b at 8.4 years), and T(0) = 43/mm3 and Vs(0) = 156/mm3 (obtained from Figure 1a,b at 8.6
years). The rates of exponential increase in Figure 2a (approximately .03, .02, .01, .005) are inversely correlated to
starting CD4+ T-cell counts, and the exponential rates of decay in Figure 2b (all about -.2) are not correlated to starting
viral levels (different viral set-points would give different values for the parallel slopes) (1,2). The lack of correlation of
viral decay rates is an indication of slower clearance of wild-type virus in the external lymphoid compartment. The time
to the downward spike in Figure 2b is correlated to starting viral levels (1). The treatment parameters c1=2.0, c2=.17,
c3=.15 and the resistance mutation parameter q=10-6 are the same in all four simulations.277 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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treatment starting values. This lack of correlation
has been reported in clinical data (1,2).
In the simulations in Figure 2, the lack of
correlation can be explained by the failure of the
treatment to suppress rapidly enough the viral
production caused by the external lymphoid
system. As this production is suppressed at faster
and faster rates, the viral exponential decay
rates approach the actual loss rates of the plasma
virus, which in this model are correlated to the
CD4+ T-cell levels. The decay rates (Figure 2b) do
not yield the actual half-life of free virus, which is
shorter. The difference is due to the incomplete
inhibition of the external lymphoid viral pro-
duction. The exponential rate of viral decay in
patients undergoing treatment is claimed to
correspond to the decay of noninfectious virus
produced by CD4+ T cells infected after
treatment begins by infectious virus present
before treatment begins (where it is assumed
that after treatment begins, all newly pro-
duced virions are noninfectious) (3). It is
claimed that the reciprocal of the viral decay
rate is the average lifespan of infected CD4+ T
cells (3). The model considered here has a
different interpretation of the effects of treat-
ment, since the prouction of virus from the
external lymphoid compartment is not im-
mediately blocked by treatment and thus
influences the viral decay rate.
In Figure 3, simulations are given with the
treatment parameter corresponding to sup-
pression of virus influx from the lymphoid
compartment higher than in Figure 1c,d and
the mutation parameter lower than in Figure 2.
In Figure 3a, remission is achieved, but in
Figure 3b,c,d, it is not (the threshold value is
indicated by the horizontal lines). The concurrence
of strong suppression of the lymphoid virus com-
partment, lower resistance mutation parameter,
Figure 3. Treatment simulations for four starting viral levels. The simulations have a common viral set-point of disease
progression, and the treatment starting values are from Figure 1a,b. For all four simulations, the treatment para-
meters are c1=2.0, c2=1.0, c3=.1, the resistance mutation parameter is q=10-7, and the threshold value is V0=.5 (indicated
by the horizontal line). The lowest starting viral level achieves remission (a), while the other three develop resistance.
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and lower viral starting value allows the
remission threshold to be reached (Figure 3a).
In Figure 4, treatment is simulated with an
even higher value of the parameter corresponding
to suppression of virus production from the
external lymphoid compartment. Remission is
achieved for the two lowest viral starting levels.
As in Figure 2a, the exponential rates of increase
of CD4+ T cells are inversely correlated to CD4+
T-cell starting values (an explanation in terms of
the relative rates of changes in the differential
equations for the CD4+ T-cell population is given
in the Appendix). The exponential rates of viral
decay (Figure 4b), however, are inversely
correlated to increasing values of starting viral
levels (in contrast with Figure 2b). When drug
inhibition of virus in the lymph compartment is
very high, the plasma viral clearance rate during
treatment approaches the plasma viral clearance
rate before treatment. In our models, it is
assumed that the plasma viral clearance rate
before treatment depends on CD4+ T-cell levels.
The inverse correlation of plasma viral clearance
rates during treatment to viral levels at the start
of treatment is thus an indicator of higher viral
clearance from the lymphoid compartment (an
explanation in terms of the relative rates of
change in the differential equation for the virus
population is given in the Appendix).
In Figure 5a, treatment data for a patient
receiving zidovudine, didanosine, and lamivudine
are simulated (18; Figure 1d). This treatment
induces a remission, even though the plasma
virus does not fall below a nondetectable level.
The plasma viral decay is approximately three
times as fast as the lymph viral decay (18). This
difference is incorporated into the treatment
parameters for the simulation in Figure 5a. The
two-phase plasma viral decay process (Figure 5a)
matches the data (18) and is a strong indication
that the rate of plasma viral decay is influenced
by the slower rate of decay in the lymph system.
Figure 4. Four treatment simulations having a common viral set-point of disease progression. The treatment starting
values are as in Figure 2. For all four simulations, the treatment parameters are c1=2.0, c2=2.0, c3=.05, the resistance
mutation parameter is q=10-8, and the threshold value is V0=2.0. Remission is achieved for the two lowest viral starting
values, but the other two develop resistance. The viral exponential decay rates are  -1.4, -.93, -.51, and -.26, which are
inversely correlated to the viral starting values (an indication of rapid suppression of virus in the external lymphoid
compartment).
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In Figure 5b, the treatment simulation (Figure
5a) is stopped at 78 weeks, whereupon the drug-
sensitive virus population rebounds sharply (8).
This simulation is consistent with the report of a
patient undergoing combined therapy who
sustained nondetectable levels of virus for 78
weeks and upon voluntarily stopping treatment
experienced high levels of virus in the blood
within 1 week (3). In this simulation the virus
would rapidly become reestablished even after
much longer treatment. The resurgence of the
virus population in the simulation is due to the
capacity of the virus to grow very quickly from
extremely low levels, which is due to the
incomplete drug-induced inhibition of the
external lymphoid viral source (18). This
incomplete inhibition can be attributed to the
presence of latently infected CD4+ T cells in the
lymphoid compartment. Resumption of treatment
in the simulation could again induce a remission.
The resurgence of virus when treatment is
stopped (Figure 5b) would hold also in all the
simulations of remission because the 0 viral level
is unstable; and if the virus is not suppressed by
drugs, it rapidly grows from even very low levels.
This instability of the 0 viral level results from
the large viral influx from the lymph system,
which is required to produce the characteristic
dynamics of HIV throughout its entire
progression.
Conclusions
Although computer models of HIV therapy
are no substitute for clinical trials, they can bring
into focus essential elements of the dynamic
processes involved. The treatment simulations
presented here identify the following qualitative
dynamic elements involved in resistance and
remission: 1) remission can occur if the viral
production in the external lymphoid tissues is
suppressed below a threshold level; 2) drug
action must be strong enough and fast enough to
drive the virus population to the threshold before
resistant virus appears and propagates; 3)
combination therapy or early treatment lowers
the capacity of the virus to mutate to resistant
strains and thus forestalls their emergence until
the threshold is reached; and 4) stopping
treatment even after an extended period of
remission may result in a rapid rebound of the
virus population.
The remission threshold is an abstract
construct, and its quantitative value is relative to
the capacity of the virus to mutate against a
specific drug regimen. In the simulations, the
threshold divides resistance and remission
outcomes, and the dynamic developments in the
first few days and weeks of drug administration
are crucial in determining the outcome of
therapy. Remission over extended time, however,
Figure 5. 5a simulates combined drug treatment data reported for a patient (18; Figure 1d). The treatment begins with
the uninfected CD4+ T-cell count at 306/mm3, the infected CD4+ T-cell count at 10/mm3, and the virus level at 21/mm3
(these values are obtained from the simulation in Figure 1a, b at 5.75 years). The treatment parameters are c1=2.0,
c2=1.0, c3=.15, the resistance threshold value is V0=3.0, and the resistance mutation parameter is q=10-7. Resistance
does not develop, and the therapy results in remission. The plasma viral level shows a two-phase exponential decay,
which is attributed to a slower drug-induced inhibition of virus in the lymphoid compartment. In 5b, the treatment
simulation in 5a is continued for 78 weeks and then stopped. The virus population rebounds rapidly when treatment
stops.280 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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may require continuing treatment to suppress
low-level viral replication in the lymphoid tis-
sues. The presence of even low-level viral
production due to latently infected CD4+ T cells
allows the possibility for the eventual evolution
of drug-resistant viral strains.
Appendix
For the model without treatment, it is
assumed that only drug-sensitive virus, uninfected
CD4+ T cells, and CD4+ T cells infected by drug-
sensitive virus are present. The equations for the
model without treatment are as follows (24):
(A.1): dT(t)/dt = S(t) - mTT(t) + p1(t)T(t)Vs(t) -
ksVs(t)T(t)
(A.2): dTs (t)/dt = ksVs(t)T(t) - mTiTs(t) -
p2(t)Ts (t)Vs (t)
(A.3): dVs (t)/dt  = p3(t)Ts (t)Vs (t) -
kvT(t)Vs(t) + Gs(t)
In (A.1) S(t) represents the external input of
uninfected CD4+ T cells from the thymus, bone
marrow, or other sources. It is assumed that
there is a deterioration of this source as the viral
level increases during the course of HIV infec-
tion. The form of this source is S(t) = S1 - S2 Vs(t)/
(Bs+Vs(t)), where Bs is a saturation constant (the
various saturation constants in the model are
designed to adjust the rate parameters to large
changes in the population levels during disease
progression or treatment). In (A.1)  mT is the death
rate of uninfected CD4+ T cells whose average
lifespan is 1/mT (25). In (A.1) the term  p1(t) T(t)
Vs(t) represents CD4+ T-cell proliferation in the
plasma due to an immune response that incor-
porates both direct and indirect effects of antigen
stimulation (p1(t) = p1/(C+Vs(t)), where C is a
saturation constant). This term accounts for the
above normal turnover of CD4+ T cells (other
forms for this production have been used, inclu-
ding a logistic approach [26]). The form assumed
here idealizes the growth mechanisms of CD4+ T
cells, since subpopulations of antigen specific
CD4+ T cells are not modeled. In (A.1) ks is the
infection rate of CD4+ T cells by virus (it is
assumed that the rate of infection is governed by
the mass action term  ks Vs(t) T(t)). In the absence
of virus the CD4+ T-cell population converges to
a steady state of S1/mT.
In (A.2) there is a gain term ks Vs(t) T(t) of CD4+
T cells infected by drug-sensitive virus, a loss term
mTi Ts(t) due to the death of these cells independent
of the virus population, and a loss term  p2(t) Ts(t)
Vs(t) dependent on the virus population due to
bursting or other causes (where p2(t) = p2/(Ci+Vs(t))
and Ci is a saturation constant). The dependence of
the loss term p2(t) Ts(t) Vs(t) on Vs(t) allows for an
increased rate of bursting of infected cells as the
immune system collapses and fewer of these cells
are removed by CD8+ T cells.
In (A.3) the virus population is increased by
the term  p3(t) Ts(t) Vs(t), where p3(t) = p3/(Ci+Vs(t)).
This term corresponds to the internal production
of virus in the blood. The dependence of this term
on Ts(t) allows for a decreased rate of viral
production in the plasma when the infected CD4+
T-cell population in the plasma collapses. Since
most of the plasma virus is contributed by the
external lymph source, the plasma virus popu-
lation still increases steeply at the end stage of
the disease. In (A.3) the virus population is
decreased by the loss term kv T(t) Vs(t), which
represents viral clearance. In (A.3) there is a
source of virus from the external lymphoid
compartment, which is represented by the term
Gs(t) = GsVs(t)/(B+Vs(t)) (B is a saturation con-
stant). This term accounts for most of the virus
present in the blood (8).
The lifespans of infected CD4+ T cells and virus
can be computed from the terms in (A.2) and (A.3)
during the asymptomatic period of infection (when
the rates of population increase are almost
balanced by the rates of population decrease). The
loss terms in (A.2) yield an average infected CD4+
T-cell lifespan of 1/mTi + p2 Vs(t)/(Ci +Vs(t)), which
decreases from = 1/mTi to 1/(mTi +p2) as Vs(t)
increases. The loss term in (A.3) yields an average
virus lifespan of 1/(kvT(t)), which increases from 1/
(kv T(0)) as T(t) decreases.
The equations for the model with treatment
are as follows:
(A.4): dT(t)/dt = S0(t) - mTT(t) + p1(t)T(t)V(t)
 - (h1(t)ksVs(t) + krVr(t)) T(t)
(A.5): dTs(t)/dt = h1(t) ksVs(t) T(t) - mTi Ts(t)
- p2(t) Ts(t) V(t)
(A.6): dTr(t)/dt = kr Vr(t) T(t) - mTi Tr(t)
 - p2(t)Tr(t) V(t)
(A.7): dVs(t)/dt = (1-q)p3(t)Ts(t)V(t) - kvT(t)Vs(t)
+ h2(t) GsVs(t)/(B+V(t))
(A.8): dVr(t)/dt = p3(t) Tr(t) V(t) + q p3(t) Ts(t)V(t)
- kv T(t) Vr(t) + Gr(V(t))Vr(t)/(B+V(t))
In the model, treatment inhibits (with a
delay) new infections of CD4+ T cells and inhibits
(with a delay) the influx of virus from the
external source. In equations (A.4) - (A.8)  V(t) =
Vs(t) + Vr(t) is the total virus population at time t,281 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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and its inclusion in the rate coefficients results in
competition between the sensitive and resistant
viral strains. In these equations, treatment is
modeled by the decreasing functions h1(t) = exp(-
c1t) (which inhibits the rate at which uninfected
CD4+ T cells become infected) and h2(t) =
maximum{exp(-c2t), c3} (which inhibits the influx
of virus from the external lymphoid compartment).
The parameters c1, c2, and c3 control the speed
and strength of the drug-induced inhibitions. The
form of the treatment function h1(t) produces an
eventual complete inhibition of infection of CD4+
T cells in the plasma but does not do so
immediately upon treatment (1-3). The form of
the treatment function  h2(t) produces a delayed
and incomplete suppression of viral influx from
the external lymphoid system (18). Treatment
does not affect the drug-resistant virus or the
CD4+ T cells infected by drug-resistant virus.
When treatment begins, it is assumed that
the source term of CD4+ T cells in equation (A.4)
has the value S0(t) = minimum{ S0 ,S1 - S2V(t)/
(Bs+V(t))}, where S0 is the value of the source of
CD4+ T cells when treatment is started (S0 is
obtained from the source function S(t) in the
model without treatment). This assumption means
that the source of CD4+ T cells does not increase
once treatment begins but may decrease if the virus
population later increases because of the develop-
ment of resistance or the cessation of treatment.
In the model, it is assumed that there is no
significant level of background resistant virus
present to substantially affect the dynamics
before treatment begins. After treatment begins,
drug-resistant virus does become significant and
is introduced into the virus population as a pro-
portion q of the drug-sensitive virus population
(19). It is not assumed that drug administration
induces resistant mutations, but only that it
gives selective advantage to them. The value of q
corresponds to the capacity of resistant variants
to mutate (larger q corresponds to monotherapy
and smaller q to combined therapy). It is assumed
that the external input of drug-resistant virus from
the lymphoid compartment is controlled by the
threshold function Gr(V), where Gr (V) = 0 if V is
less than the threshold value V0 and Gr (V) = Gs if
V is greater than V0. This assumption means that
the capacity of the resistant virus to become
established requires that the total virus popu-
lation level remain above the threshold V0.
The lack of correlation of the slopes in Figure
2b to starting CD4+ T-cell counts in Figure 2a can
be explained in terms of equation (A.7). When
treatment starts at time t0, Gs/(B+V(t0))  » kv T(t0)
(since the virus population is changing very
slowly before treatment starts and the major source
of virus present is due to the external source).
After treatment starts, dVs(t)/dt » - r(t)Vs(t),
where  r(t) = c2 (t) Gs/(B+V(t)) - kv T(t). If c2(t) » 1
(which corresponds to slow clearance of the
external compartment), then r(t) » 0 and  r(t)
does not have a strong dependence on T(t0) (as in
Figure 2b). If c2 (t) » 0 (which corresponds to rapid
clearance of the external lymphoid compartment),
then  r(t)  » k v T(t) and thus shows a strong
dependence on T(t0) (as in Figure 4b). A similar
argument using equation (A.4) shows that
when c1(t) » 0  (as in Figures 2a and 4a), then the
exponential rates of increase in CD4+ T-cell
counts are inversely correlated to treatment
CD4+ T-cell starting values.
The models described in this paper have
evolved from earlier models by the authors
(24,26-28). A major goal of the present work is to
align the model simulations with an expanding
base of data for HIV dynamics. The construction
of the present models is based in part on
theoretical assumptions about the rate changes
of the interacting populations and in part on
simulation of their known dynamic properties.
Another major goal of the present work is to
derive insight into the qualitative distinctions
between monotherapy resistance and combined-
therapy remission. In the model (A.4)-(A.8), this
distinction resides in the mutation parameter q,
which corresponds to the capacity of resistant
virus to arise as a proportion of sensitive virus
when the total virus population is above the
threshold value V0. When q is large (monotherapy),
the total virus population does not fall below V0,
and resistant virus becomes established. When q
is small (combined therapy) and the total virus
population is brought below V0 sufficiently fast in
the first days and weeks of treatment, the
resistant virus population cannot grow.
The models of this paper differ from earlier
models (1-3). The models here describe disease
progression, whereas others (1-3) describe short
intervals of treatment from presumed dynamic
steady states. The models here describe dyna-
mics in the plasma, whereas others (1,3) describe
dynamics in the total body. The models of this
paper distinguish between the behavior of virus
in the plasma and in the lymph system. In the
models here, the virus increases steeply in the282 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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Table. Parameter values for the models
Parameters and Constants Values
m T = mortality rate of uninfected CD4+ T cells 0.005/day
mTi = mortality rate of infected CD4 + T cells 0.25/day
ks =  rate CD4+ T cells are infected by sensitive virus 0.0005 mm3/day
kr = rate CD4+ T cells are infected by resistant virus 0.0005 mm3/day
kv =  rate of virus loss due to the immune response 0.0062 mm3/day
p1 = production rate of uninfected CD4+ T cells 0.025/day
p2 = production rate of infected CD4+ T cells 0.25/day
p3 = production rate of virus in the blood 0.8/day
Gs = external lymphoid sensitive virus source constant 41.2/mm3 day
Gr = external lymphoid resistant virus source constant specified in text
V0 = threshold value for remission specified in figure legends
q = proportion of drug-resistant virus produced from specified in figure legends
wild-type virus
C = half saturation constant of uninfected CD4+ T cells 47.0/mm3
Ci = half saturation constant of infected CD4+ T cells 47.0/mm3
B = half saturation constant of external virus input 2.0/mm3
Bs = half saturation constant of CD4+ T-cell source 13.8/mm3
S1 = source of CD4+ T cells in absence of the disease 4.0/mm3 day
S2 = reduction constant of CD4+ T-cell source 2.8/mm3 day
c1 = treatment parameter for suppression of the rate of specified in figure legends
CD4+ T-cell infection by virus
c2 = treatment parameter for suppression of the rate of virus specified in figure legends
contributed by the external lymphoid compartment
c3 = treatment parameter for maximal  suppression of virus specified in figure legends
contributed by the external lymphoid compartment
h1 = treatment function for inhibition of the rate at which virus specified in text
infects uninfected CD4+ T cells
h 2 = treatment function for inhibition of the rate of virus specified in text
influx from the external lymphoid system virus
plasma but saturates in the lymph system. The
assumption of a large saturating external source
of virus to the plasma is required in this model for
the simulation of data.
The models of this paper also assume that the
viral clearance rate depends on the CD4+ T-cell
level, whereas other models (1-3) assume that this
rate is constant. This last assumption is required
in our models to obtain the dynamics of disease
progression. This assumption is reasonable in
understanding how the virus population can
increase steeply in the plasma as the CD4+ T-cell
population in the plasma collapses. If the viral
clearance rate in the plasma is independent of
CD4+ T-cell levels, the steep increase of plasma
virus (as much as 100-fold) at disease end
would have to result from increased production.
But the CD4+ T-cell population in the plasma
collapses to near 0 so that this population can-
not account for the high viral increase. In the
models here, this steep increase of plasma virus
results from the collapse of the immune response
(which means that the plasma viral clearance
rate should depend on CD4+ T-cell levels) and
from a continuing influx of virus from the
saturated external lymph source.
We provide a list of parameter values for the
models with and without treatment (Table).283 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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